Elenco degli articoli con argomento «brodalumab»

Dermatologia

17 lug 2023

Interleukin-17 pathway inhibition with brodalumab in early systemic sclerosis

Analysis of a single-arm, open-label, phase 1 trial

15 ott 2019

Psoriasi: farmaci biologici sempre più efficaci e sicuri navigation-next-alternate

Gli anticorpi migliorano significativamente i sintomi della malattia. No al “fai da te”. Sul web troppi video privi di contenuto scientifico

24 ott 2017

Brodalumab Achieves Superior Lesion Clearance Compared With Secukinumab and Ustekinumab in Moderate-to-Severe Psoriasis navigation-next-alternate

More patients with moderate-to-severe psoriasis achieved "clear" or "almost clear" status with brodalumab than with secukinumab using Psoriasis Area and Severity (PASI) scores

10 ott 2017

Brodalumab Shows Sustained Efficacy in Treating Moderate-to-Severe Psoriasis navigation-next-alternate

Brodalumab achieved high levels of lesion clearance in the majority of patients with moderate-to-severe psoriasis, with results sustained through 120 weeks

10 ott 2017

Switching to Brodalumab From Ustekinumab Improves Clearance in Moderate-to-Severe Psoriasis navigation-next-alternate

Patients with moderate-to-severe psoriasis that did not adequately respond to ustekinumab achieve high levels of lesion clearance after switching to brodalumab rescue therapy

27 feb 2017

FDA Approves Brodalumab to Treat Psoriasis navigation-next-alternate

The US Food and Drug Administration (FDA) has approved brodalumab (Siliq) to treat adults with moderate-to-severe plaque psoriasis. Brodalumab is administered as an injection.

02 ott 2015

Investigational Drug Brodalumab Effective for Patients With Psoriasis navigation-next-alternate

An experimental, biologic treatment, brodalumab, appears to be more effective than ustekinumab in reducing psoriasis symptoms